Wealth Enhancement Advisory Services
NTLA icon

Wealth Enhancement Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Buy
19,846
+1,038
+6% +$14.5K ﹤0.01% 3261
2026
Q1 		$247K Buy
18,808
+8,463
+82% +$108K ﹤0.01% 2962
2025
Q4 		$101K Buy
+10,345
New +$142K ﹤0.01% 3428
2025
Q2 		– Sell
-13,789
Closed -$98K – 3453
2025
Q1 		$98K Buy
+13,789
New +$139K ﹤0.01% 2761

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Wealth Enhancement Advisory Services's NTLA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Intellia Therapeutics (NTLA) stake by 5.5% in Q2 2026, buying an estimated $14.5K and bringing the position to 19,846 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #3261.

Wealth Enhancement Advisory Services first reported a position in NTLA in Q1 2025 and has held it in 4 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 19,846 shares of Intellia Therapeutics worth $282K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 1,038 Intellia Therapeutics shares in Q2 2026, an estimated $14.5K.
  • Intellia Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3261 holding.
  • Wealth Enhancement Advisory Services first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.